Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease -- Levine et al. 111 (4): 2470 Data Supplement - <font size="3">Supplemental materials for: Levine et al</font> -- Blood

Blood, Vol. 111, Issue 4, 2470-2475, February 15, 2008

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
Blood Levine et al. 111: 2470

Supplemental materials for: Levine et al

Files in this Data Supplement:

Table S1. Patient characteristics by trial enrollment (PDF, 15.6 KB)
Table S2. Complete response rates at four weeks according to pilot or phase II trial enrollment (PDF, 16.9 KB)
Table S3. Complete response rates at four weeks according to treatment group by conditioning regimen (PDF, 12.9 KB)
Figure S1. Time to onset of chronic GVHD for patients treated with steroids alone or etanercept plus steroids (JPG, 21.1 KB) -
The one year cumulative incidence of chronic GVHD is shown for patients treated with steroids alone (56%, n=99, dotted line) or etanercept plus steroids (57%, n=61, solid line). Relapse prior to chronic GVHD was treated as a censoring event and death prior to chronic GVHD as a competing event.